摘要
美国罕用药物法案本意是用来鼓励制药产业研发和生产不具有商业价值的罕见药物,但是这项政策却对美国生物制药产业起到了关键性的推动作用。本文首先介绍了美国罕用药物法案颁布的背景及其所提供的优惠政策并回顾了颁布以来所取得的成就,然后以美国最成功的四家生物科技公司的发展为案例分析了罕用药物法案对美国生物医药产业的影响,结果表明通过科技推动和经济拉动罕用药物政策不但鼓励了罕用药的研发和生产还成功地推动了美国生物医药产业发展。
The US Orphan Drug Act （ODA） aims at promoting the development of orphan drugs that have limited commercial value, but this policy gives an enormous impetus to the US biopharmaceutical industry. In this article, firstly we introduce the background of ODA and its incentives, and then review its achievements. Based on the case study of the four most successful biotechnology companies, we analyze the influence of ODA on US biopharmaceutical industry. The results show that by the means of technology push and economy pull, ODA have not only stimulated the R＆D and manufacture of orphan drugs but also played a positive role in propelling the development of US biopharmaeeutical industry.
出处
《中国科技论坛》
CSSCI
北大核心
2014年第11期90-96,共7页
Forum on Science and Technology in China
关键词
罕用药物法案
生物制药产业
生物科技公司
Orphan Drug Act
Biopharmaceutical industry
Biotechnology companies
